Literature DB >> 1145407

Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome.

J C Thompson, D D Reeder, H V Villar, H R Fender.   

Abstract

With better methods of diagnosis, patients will be identified earlier in the course of their disease and will often have atypical and borderline manifestations of the syndrome. Serum gastrin measurements with calcium and especially with secretin challenge will be the most important method of diagnosis. Any patient with acid hypersecretion who has a high serum gastrin level that does higher on secretin infusion should be considered to have the Zollinger-Ellison syndrome. A firm diagnosis of the Zollinger-Ellison syndrome should be made, if at all possible, prior to operation. At operation, a thorough search of the pancreas, duodenum, stomach, greater and lesser omentum and liver should be made for primary and secondary gastrinomas. If the preoperative data firmly establish the diagnosis of the Zollinger-Ellison syndrome, a total gastrectomy should be carried out even if no primary tumor is found. Similarly, a total gastrectomy should be done even if there are massive hepatic metastases. If total gastrectomy is not performed, the patient is apt to die of complications of acid hypersecretion. The only possible exceptions to the rule of always performing a total gastrectomy are in asymptomatic patients with easily excisable tumors or patients with tumors of the duodenum that are easily excisable, providing that in both instances after the excision of the tumor the output of gastric acid as measured at operation is immediately halted. All possible metastatic tumor tissue should be removed. The more tumor tissue removed, the longer the patient will survive. Metastases should be treated aggressively. They do not disappear after total gastrectomy in our experience, and they may kill patients. Patients should be followed after operation with serial measurements of serum gastrin concentrations and by hepatic scintillation scans and hepatic angiography. If hepatic metastases develop, intrahepatic artery infusions of 5-fluorouracil may slow tumor growth.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1145407

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  28 in total

1.  Current status of the apudomas.

Authors:  R B Welbourn
Journal:  Ann Surg       Date:  1977-01       Impact factor: 12.969

Review 2.  Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; R T Jensen
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

3.  Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.

Authors:  M J Collen; M J Sheridan
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

4.  Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP).

Authors:  H V Villar; H R Fender; P L Rayford; S R Bloom; N I Ramus; J C Thompson
Journal:  Ann Surg       Date:  1976-07       Impact factor: 12.969

5.  Criteria for the glucagon provocative test in the diagnosis of gastrinoma.

Authors:  Chikashi Shibata; Masayuki Kakyo; Makoto Kinouchi; Naoki Tanaka; Koh Miura; Takeshi Naitoh; Hitoshi Ogawa; Fuyuhiko Motoi; Shinichi Egawa; Tatsuya Ueno; Hiroo Naito; Michiaki Unno
Journal:  Surg Today       Date:  2012-09-16       Impact factor: 2.549

6.  Zollinger-Ellison syndrome presenting as esophageal stricture.

Authors:  H J Smith; H J Chapa; W J Kilman; W L Watkins
Journal:  Gastrointest Radiol       Date:  1979-11-15

7.  Gastroduodenal fistula in the Zollinger-Ellison syndrome.

Authors:  R J Machell; A P Dick; W G Everett
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

8.  Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome.

Authors:  C G Lamers; J H Van Tongeren
Journal:  Gut       Date:  1977-02       Impact factor: 23.059

9.  Clinical significance of glucagon provocation test in the diagnosis of hypergastrinemia.

Authors:  C Nakanome; A Ishimori; Y Goto; T Yamazaki; J Kameyama; I Sasaki; M Inui; Y Furukawa; K Komatsu
Journal:  Gastroenterol Jpn       Date:  1981

10.  A review of the Zollinger-Ellison syndrome--with particular reference to a patient treated with cimetidine.

Authors:  R J Wyke; G L Hill; A T Axon
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.